These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
394 related articles for article (PubMed ID: 30737299)
1. One-Step Kuo HT; Lepage ML; Lin KS; Pan J; Zhang Z; Liu Z; Pryyma A; Zhang C; Merkens H; Roxin A; Perrin DM; Bénard F J Nucl Med; 2019 Aug; 60(8):1160-1166. PubMed ID: 30737299 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and pre-clinical evaluation of a new class of high-affinity Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991 [TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003 [TBL] [Abstract][Full Text] [Related]
4. Preclinical Evaluation and Pilot Clinical Study of Al Liu T; Liu C; Xu X; Liu F; Guo X; Li N; Wang X; Yang J; Yang X; Zhu H; Yang Z J Nucl Med; 2019 Sep; 60(9):1284-1292. PubMed ID: 30796170 [TBL] [Abstract][Full Text] [Related]
5. In Vitro and In Vivo Characterization of an Lütje S; Franssen GM; Herrmann K; Boerman OC; Rijpkema M; Gotthardt M; Heskamp S J Nucl Med; 2019 Jul; 60(7):1017-1022. PubMed ID: 30655329 [TBL] [Abstract][Full Text] [Related]
6. Targeting Prostate-Specific Membrane Antigen (PSMA) with F-18-Labeled Compounds: the Influence of Prosthetic Groups on Tumor Uptake and Clearance Profile. Bouvet V; Wuest M; Bailey JJ; Bergman C; Janzen N; Valliant JF; Wuest F Mol Imaging Biol; 2017 Dec; 19(6):923-932. PubMed ID: 28639122 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer. Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647 [TBL] [Abstract][Full Text] [Related]
8. Effects of Linker Modification on Tumor-to-Kidney Contrast of Kuo HT; Pan J; Zhang Z; Lau J; Merkens H; Zhang C; Colpo N; Lin KS; Bénard F Mol Pharm; 2018 Aug; 15(8):3502-3511. PubMed ID: 29920108 [No Abstract] [Full Text] [Related]
9. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Benešová M; Schäfer M; Bauder-Wüst U; Afshar-Oromieh A; Kratochwil C; Mier W; Haberkorn U; Kopka K; Eder M J Nucl Med; 2015 Jun; 56(6):914-20. PubMed ID: 25883127 [TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of Cardinale J; Schäfer M; Benešová M; Bauder-Wüst U; Leotta K; Eder M; Neels OC; Haberkorn U; Giesel FL; Kopka K J Nucl Med; 2017 Mar; 58(3):425-431. PubMed ID: 27789722 [TBL] [Abstract][Full Text] [Related]
11. Development of Potemkin R; Strauch B; Kuwert T; Prante O; Maschauer S Mol Pharm; 2020 Mar; 17(3):933-943. PubMed ID: 32011889 [TBL] [Abstract][Full Text] [Related]
12. Radiohybrid Ligands: A Novel Tracer Concept Exemplified by Wurzer A; Di Carlo D; Schmidt A; Beck R; Eiber M; Schwaiger M; Wester HJ J Nucl Med; 2020 May; 61(5):735-742. PubMed ID: 31862804 [TBL] [Abstract][Full Text] [Related]
13. Basaco Bernabeu T; Mansi R; Del Pozzo L; Zanger S; Gaonkar RH; McDougall L; De Rose F; Jaafar-Thiel L; Herz M; Eiber M; Ulaner GA; Weber WA; Fani M J Nucl Med; 2024 Sep; 65(9):1427-1434. PubMed ID: 39025646 [TBL] [Abstract][Full Text] [Related]
14. Validation of a [Al Al-Momani E; Israel I; Samnick S Appl Radiat Isot; 2017 Dec; 130():102-108. PubMed ID: 28950199 [TBL] [Abstract][Full Text] [Related]
15. 2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. Chen Y; Pullambhatla M; Foss CA; Byun Y; Nimmagadda S; Senthamizhchelvan S; Sgouros G; Mease RC; Pomper MG Clin Cancer Res; 2011 Dec; 17(24):7645-53. PubMed ID: 22042970 [TBL] [Abstract][Full Text] [Related]
16. Assessment of an 18F-labeled phosphoramidate peptidomimetic as a new prostate-specific membrane antigen-targeted imaging agent for prostate cancer. Lapi SE; Wahnishe H; Pham D; Wu LY; Nedrow-Byers JR; Liu T; Vejdani K; VanBrocklin HF; Berkman CE; Jones EF J Nucl Med; 2009 Dec; 50(12):2042-8. PubMed ID: 19910433 [TBL] [Abstract][Full Text] [Related]
17. F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients. Giesel FL; Hadaschik B; Cardinale J; Radtke J; Vinsensia M; Lehnert W; Kesch C; Tolstov Y; Singer S; Grabe N; Duensing S; Schäfer M; Neels OC; Mier W; Haberkorn U; Kopka K; Kratochwil C Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):678-688. PubMed ID: 27889802 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer. Schottelius M; Wurzer A; Wissmiller K; Beck R; Koch M; Gorpas D; Notni J; Buckle T; van Oosterom MN; Steiger K; Ntziachristos V; Schwaiger M; van Leeuwen FWB; Wester HJ J Nucl Med; 2019 Jan; 60(1):71-78. PubMed ID: 30237214 [TBL] [Abstract][Full Text] [Related]
19. Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes. Carlos Dos Santos J; Beijer B; Bauder-Wüst U; Schäfer M; Leotta K; Eder M; Benešová M; Kleist C; Giesel F; Kratochwil C; Kopka K; Haberkorn U; Mier W J Nucl Med; 2020 Jan; 61(1):70-79. PubMed ID: 31541034 [TBL] [Abstract][Full Text] [Related]
20. Lee BS; Chu SY; Jung WJ; Jeong HJ; Lee K; Kim MH; Kim MH; Chi DY; Ahn H; Lee YJ; Lee KC; Lim SM Prostate; 2020 Dec; 80(16):1383-1393. PubMed ID: 32960990 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]